KR101088942B1 - Ｅｐ2 작용제 - Google Patents

Ｅｐ2 작용제 Download PDF

Info

Publication number
KR101088942B1
KR101088942B1 KR1020097001522A KR20097001522A KR101088942B1 KR 101088942 B1 KR101088942 B1 KR 101088942B1 KR 1020097001522 A KR1020097001522 A KR 1020097001522A KR 20097001522 A KR20097001522 A KR 20097001522A KR 101088942 B1 KR101088942 B1 KR 101088942B1
Authority
KR
South Korea
Prior art keywords
compounds
compound
alkyl
intraocular pressure
groups
Prior art date
Application number
KR1020097001522A
Other languages
English (en)
Korean (ko)
Other versions
KR20090023507A (ko
Inventor
가네쉬 프라산나
챨스 플로이드 보스워스
폰테인 제니퍼 앤 라
Original Assignee
화이자 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 프로덕츠 인코포레이티드 filed Critical 화이자 프로덕츠 인코포레이티드
Publication of KR20090023507A publication Critical patent/KR20090023507A/ko
Application granted granted Critical
Publication of KR101088942B1 publication Critical patent/KR101088942B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
KR1020097001522A 2006-07-28 2007-07-16 Ｅｐ2 작용제 KR101088942B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US60/833,907 2006-07-28
US94192307P 2007-06-04 2007-06-04
US60/941,923 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (en) 2006-07-28 2007-07-16 Ep2 agonists

Publications (2)

Publication Number Publication Date
KR20090023507A KR20090023507A (ko) 2009-03-04
KR101088942B1 true KR101088942B1 (ko) 2011-12-01

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001522A KR101088942B1 (ko) 2006-07-28 2007-07-16 Ｅｐ2 작용제

Country Status (26)

Country Link
US (2) US7622475B2 (es)
EP (1) EP2059507B1 (es)
JP (1) JP4583500B2 (es)
KR (1) KR101088942B1 (es)
AP (1) AP2009004754A0 (es)
AR (1) AR062122A1 (es)
AU (1) AU2007280130B2 (es)
BR (1) BRPI0714683A2 (es)
CA (1) CA2659184C (es)
CL (1) CL2007002207A1 (es)
CR (1) CR10554A (es)
EA (1) EA200970067A1 (es)
EC (1) ECSP099071A (es)
GT (1) GT200700064A (es)
HK (1) HK1133876A1 (es)
IL (1) IL196355A0 (es)
MA (1) MA30604B1 (es)
MX (1) MX2009001062A (es)
NO (1) NO20090738L (es)
NZ (1) NZ573964A (es)
PE (1) PE20080408A1 (es)
RS (1) RS20090002A (es)
TN (1) TN2009000028A1 (es)
TW (1) TWI372757B (es)
UY (1) UY30511A1 (es)
WO (1) WO2008015517A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264009T3 (pl) 2008-03-12 2019-07-31 Ube Industries, Ltd. Związek stanowiący kwas pirydyloaminooctowy
SI2415763T1 (sl) 2009-03-30 2016-05-31 Ube Industries, Ltd. Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
JPWO2011030864A1 (ja) * 2009-09-11 2013-02-07 宇部興産株式会社 アニリン化合物
AU2010336248A1 (en) * 2009-12-25 2012-08-02 Ube Industries, Ltd. Aminopyridine compound
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
SG11201400555SA (en) 2011-09-16 2014-04-28 Fovea Pharmaceuticals Aniline derivatives,their preparation and their therapeutic application
CN104703598A (zh) * 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
CN104507906B (zh) 2012-05-03 2017-04-12 塔科达有限责任公司 新的ep2受体激动剂
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
WO2014157672A1 (ja) 2013-03-28 2014-10-02 宇部興産株式会社 置換ビアリール化合物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
TWI755356B (zh) * 2015-07-01 2022-02-21 日商參天製藥股份有限公司 含檸檬酸酯之緩釋劑之用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078261A1 (en) 1997-10-10 2003-04-24 Cameron Kimberly O. Prostaglandin agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
EP1000619A3 (en) 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
RU2004116318A (ru) 2001-11-30 2005-03-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции и споосбы введения селективных агонистов ep2-рецептора
WO2003064391A1 (en) * 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
CN1859903A (zh) 2003-03-04 2006-11-08 辉瑞产品公司 Ep2选择性受体激动剂在药物治疗中的应用
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078261A1 (en) 1997-10-10 2003-04-24 Cameron Kimberly O. Prostaglandin agonists

Also Published As

Publication number Publication date
JP4583500B2 (ja) 2010-11-17
US20100105905A1 (en) 2010-04-29
EP2059507A2 (en) 2009-05-20
MX2009001062A (es) 2009-02-06
ECSP099071A (es) 2009-02-27
TW200817360A (en) 2008-04-16
CL2007002207A1 (es) 2008-02-01
PE20080408A1 (es) 2008-04-28
NO20090738L (no) 2009-04-27
MA30604B1 (fr) 2009-07-01
EP2059507B1 (en) 2013-03-20
NZ573964A (en) 2010-11-26
JP2009544751A (ja) 2009-12-17
AR062122A1 (es) 2008-10-15
TWI372757B (en) 2012-09-21
CR10554A (es) 2009-02-10
TN2009000028A1 (fr) 2010-08-19
GT200700064A (es) 2009-06-18
IL196355A0 (en) 2009-09-22
US20080045545A1 (en) 2008-02-21
CA2659184A1 (en) 2008-02-07
UY30511A1 (es) 2008-02-29
AP2009004754A0 (en) 2009-02-28
CA2659184C (en) 2012-02-21
AU2007280130A1 (en) 2008-02-07
WO2008015517A3 (en) 2008-06-12
WO2008015517A2 (en) 2008-02-07
BRPI0714683A2 (pt) 2013-03-26
HK1133876A1 (en) 2010-04-09
RS20090002A (en) 2010-06-30
KR20090023507A (ko) 2009-03-04
US7622475B2 (en) 2009-11-24
EA200970067A1 (ru) 2009-08-28
AU2007280130B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
KR101088942B1 (ko) Ｅｐ2 작용제
JP7057317B2 (ja) 疾患の治療のための二重機構阻害剤
JP5980846B2 (ja) ベータおよびガンマ−アミノ−イソキノリンアミド化合物および置換ベンズアミド化合物
KR20180134849A (ko) 라이실 옥시다제의 할로알릴아민 인돌 및 아자인돌 유도체 억제제 및 이의 용도
US8030489B2 (en) Ornithine derivative
KR20190026001A (ko) 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
EP2831072A1 (en) Novel sphingosine 1-phosphate receptor antagonists
JP2021515787A (ja) アミノ−ベンゾイソチアゾール及びアミノ−ベンゾイソチアジアゾールのアミド化合物
JP2022547079A (ja) てんかんを治療する方法を使用しててんかんを治療する方法
JPH11500436A (ja) １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途
CN101495452B (zh) Ep2激动剂
KR20000048715A (ko) Ｎｍｄａ (ｎ-메틸-ｄ-아스파르테이트) 길항제
PT1730103E (pt) Derivados formamida uteis como adrenoceptores

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee